Finance

Beta
Lists
LRMR:NASDAQ
Larimar Therapeutics Inc
$3.74
+1.91%
(+0.070) 1D
Jul 17, 9:57:04 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LRMR...
Open
$3.61
High
$3.76
Low
$3.61
Mkt. cap
386.96M
Avg. vol.
2.77M
Volume
106.20K
52-wk high
$6.42
52-wk low
$2.72
EPS
-$2.08
Beta
0.84
Shares outstanding
103.88M
No. of employees
71
Open
$3.61
High
$3.76
Low
$3.61
Mkt. cap
386.96M
Avg. vol.
2.77M
Volume
106.20K
52-wk high
$6.42
52-wk low
$2.72
EPS
-$2.08
Beta
0.84
Shares outstanding
103.88M
No. of employees
71
News stories
From sources across the web
About Larimar Therapeutics Inc
CEO-
Employees71
Founded2005
HeadquartersBala Cynwyd, Pennsylvania, United States
SectorBiotechnology
Websitelarimartx.com
Analyst ratings
Based on 7 analysts giving stock ratings to LRMR in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for LRMR in the last 3 months.
Highest
Current $3.74
$25.00 (+568.45%)
Average
$12.50 (+234.22%)
Lowest
$5.00 (+33.69%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Initiated
$10.00
+167.4%
07/02/2026
Laura Chico
Wedbush
Buy
Maintained
$12.00
+220.9%
06/30/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
$5.00
+33.7%
06/30/2026
Tessa Romero
J.P. Morgan
Buy
Reiterated
$9.00
+140.6%
06/29/2026
Samantha Semenkow
Citi
Buy
Maintained
$14.00
+274.3%
06/30/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
06/29/2026
Francois Brisebois
LifeSci Capital
Buy
Maintained
$25.00
+568.4%
06/29/2026
Catherine Novack
JonesTrading
Buy
Maintained
$13.00
+247.6%
02/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
23.27M
44.83M
59.17M
24.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.52M
4.67M
4.84M
6.19M
Operating expense
27.79M
49.50M
64.02M
31.12M
Total operating expenses
27.79M
49.50M
64.02M
31.12M
Operating income
-27.79M
-49.50M
-64.02M
-31.12M
Other non operating income
1.61M
1.79M
1.52M
1.50M
EBT including unusual items
-26.18M
-47.71M
-62.50M
-29.61M
EBT excluding unusual items
-26.18M
-47.71M
-62.50M
-29.61M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.18M
-47.71M
-62.50M
-29.61M
Net profit margin
-
-
-
-
Earnings per share
-0.41
-0.61
-0.73
-0.31
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.70M
-49.41M
-63.93M
-31.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer